Nathan Weinstein
Stock Analyst at Aegis Capital
(0.30)
# 4,012
Out of 4,814 analysts
61
Total ratings
13.33%
Success rate
-26.12%
Average return
Main Sectors:
Stocks Rated by Nathan Weinstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EVGN Evogene | Maintains: Buy | $100 → $80 | $0.95 | +8,321.05% | 2 | Sep 12, 2022 | |
| DRIO DarioHealth | Maintains: Buy | $20 → $15 | $0.75 | +1,906.96% | 6 | Aug 18, 2022 | |
| VNRX VolitionRx | Maintains: Buy | $9 → $6 | $0.47 | +1,176.60% | 5 | Aug 15, 2022 | |
| IMUX Immunic | Maintains: Buy | $40 → $35 | $0.98 | +3,489.38% | 2 | Aug 8, 2022 | |
| STXS Stereotaxis | Initiates: Buy | $6 | $1.83 | +227.87% | 1 | Jul 12, 2022 | |
| ORMP Oramed Pharmaceuticals | Maintains: Buy | $35 → $30 | $2.16 | +1,288.89% | 5 | May 16, 2022 | |
| TRVI Trevi Therapeutics | Initiates: Buy | $10 | $6.09 | +64.20% | 1 | Mar 29, 2022 | |
| MDWD MediWound | Maintains: Buy | $63 → $49 | $17.09 | +186.72% | 4 | Mar 21, 2022 | |
| ENVB Enveric Biosciences | Downgrades: Hold | $5,250 → $150 | $1.17 | +12,720.51% | 2 | Mar 8, 2022 | |
| CING Cingulate | Initiates: Buy | $2,160 | $4.23 | +50,963.83% | 1 | Jan 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $1.10 | +2,627.27% | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $10 | $0.58 | +1,612.92% | 2 | Nov 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $160 | $19.44 | +723.05% | 2 | Sep 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $56 | $21.40 | +161.68% | 2 | Sep 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $27 | $1.48 | +1,724.32% | 3 | Aug 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $35 | $0.90 | +3,807.12% | 4 | Jun 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $1.80 | +566.67% | 1 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $8.92 | +740.81% | 1 | Jan 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $11 | $0.48 | +2,191.19% | 3 | Oct 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $180 | $2.10 | +8,471.43% | 1 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $9 | $0.41 | +2,111.85% | 3 | Aug 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $5.38 | +160.06% | 1 | Jul 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $220 | $9.24 | +2,282.24% | 7 | May 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8.5 | $2.78 | +206.31% | 1 | Mar 23, 2020 |
Evogene
Sep 12, 2022
Maintains: Buy
Price Target: $100 → $80
Current: $0.95
Upside: +8,321.05%
DarioHealth
Aug 18, 2022
Maintains: Buy
Price Target: $20 → $15
Current: $0.75
Upside: +1,906.96%
VolitionRx
Aug 15, 2022
Maintains: Buy
Price Target: $9 → $6
Current: $0.47
Upside: +1,176.60%
Immunic
Aug 8, 2022
Maintains: Buy
Price Target: $40 → $35
Current: $0.98
Upside: +3,489.38%
Stereotaxis
Jul 12, 2022
Initiates: Buy
Price Target: $6
Current: $1.83
Upside: +227.87%
Oramed Pharmaceuticals
May 16, 2022
Maintains: Buy
Price Target: $35 → $30
Current: $2.16
Upside: +1,288.89%
Trevi Therapeutics
Mar 29, 2022
Initiates: Buy
Price Target: $10
Current: $6.09
Upside: +64.20%
MediWound
Mar 21, 2022
Maintains: Buy
Price Target: $63 → $49
Current: $17.09
Upside: +186.72%
Enveric Biosciences
Mar 8, 2022
Downgrades: Hold
Price Target: $5,250 → $150
Current: $1.17
Upside: +12,720.51%
Cingulate
Jan 11, 2022
Initiates: Buy
Price Target: $2,160
Current: $4.23
Upside: +50,963.83%
Dec 7, 2021
Initiates: Buy
Price Target: $30
Current: $1.10
Upside: +2,627.27%
Nov 1, 2021
Maintains: Buy
Price Target: $9 → $10
Current: $0.58
Upside: +1,612.92%
Sep 22, 2021
Maintains: Buy
Price Target: $180 → $160
Current: $19.44
Upside: +723.05%
Sep 9, 2021
Maintains: Buy
Price Target: $60 → $56
Current: $21.40
Upside: +161.68%
Aug 17, 2021
Maintains: Buy
Price Target: $26 → $27
Current: $1.48
Upside: +1,724.32%
Jun 7, 2021
Maintains: Buy
Price Target: $40 → $35
Current: $0.90
Upside: +3,807.12%
Mar 22, 2021
Initiates: Buy
Price Target: $12
Current: $1.80
Upside: +566.67%
Jan 26, 2021
Initiates: Buy
Price Target: $75
Current: $8.92
Upside: +740.81%
Oct 19, 2020
Maintains: Buy
Price Target: $13 → $11
Current: $0.48
Upside: +2,191.19%
Oct 8, 2020
Initiates: Buy
Price Target: $180
Current: $2.10
Upside: +8,471.43%
Aug 3, 2020
Maintains: Buy
Price Target: $13 → $9
Current: $0.41
Upside: +2,111.85%
Jul 13, 2020
Initiates: Buy
Price Target: $14
Current: $5.38
Upside: +160.06%
May 4, 2020
Maintains: Buy
Price Target: $180 → $220
Current: $9.24
Upside: +2,282.24%
Mar 23, 2020
Initiates: Buy
Price Target: $8.5
Current: $2.78
Upside: +206.31%